Abstract
Systemic fungal infections of humans and economically important animals are increasingly common throughout the world. These infections are severe and often hard to treat with existing safe, oral medications. Thus there has been increasing research on alternatives resulting in study of natural and synthetic inhibitors of 1,3-β-Glucan synthase (GS) and chitin synthase (CS)-enzymes important in the biosynthesis of fungal cell walls that are not utilized in human biochemistry. Some such agents have recently been introduced into parenteral clinical use. There is hope that safe agents of this type with oral activity may yet emerge. This active area of research and its historic context with alternative agents is reviewed herein.
Keywords: Antifungal drugs, amphotericin B, conazoles, flucytosine, morpholine, 1, 3-β-glucan synthase inhibitors, echinocandins, triterpene glycosides, kramerixin, chitin synthase inhibitors.
Current Medicinal Chemistry
Title:Recent Progress in the Chemotherapy of Human Fungal Diseases. Emphasis on 1,3-β-Glucan Synthase and Chitin Synthase Inhibitors
Volume: 20 Issue: 38
Author(s): Anwer Basha, Fatima Basha, Syed Kashif Ali, Paul R. Hanson, Lester A. Mitscher and Berl R. Oakley
Affiliation:
Keywords: Antifungal drugs, amphotericin B, conazoles, flucytosine, morpholine, 1, 3-β-glucan synthase inhibitors, echinocandins, triterpene glycosides, kramerixin, chitin synthase inhibitors.
Abstract: Systemic fungal infections of humans and economically important animals are increasingly common throughout the world. These infections are severe and often hard to treat with existing safe, oral medications. Thus there has been increasing research on alternatives resulting in study of natural and synthetic inhibitors of 1,3-β-Glucan synthase (GS) and chitin synthase (CS)-enzymes important in the biosynthesis of fungal cell walls that are not utilized in human biochemistry. Some such agents have recently been introduced into parenteral clinical use. There is hope that safe agents of this type with oral activity may yet emerge. This active area of research and its historic context with alternative agents is reviewed herein.
Export Options
About this article
Cite this article as:
Basha Anwer, Basha Fatima, Ali Kashif Syed, Hanson R. Paul, Mitscher A. Lester and Oakley R. Berl, Recent Progress in the Chemotherapy of Human Fungal Diseases. Emphasis on 1,3-β-Glucan Synthase and Chitin Synthase Inhibitors, Current Medicinal Chemistry 2013; 20 (38) . https://dx.doi.org/10.2174/092986732038131128102220
DOI https://dx.doi.org/10.2174/092986732038131128102220 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Proposed Screening Paradigm for Discovery of Covalent Inhibitor Drugs
Drug Metabolism Letters Novel and Emerging Drugs for Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia
Current Drug Metabolism Role of Iron Deficiency and Overload in the Pathogenesis of Diabetes and Diabetic Complications
Current Medicinal Chemistry Prognostic Markers in Small Cell Lung Cancer
Current Cancer Therapy Reviews Oncogenic Signaling in Acute Myeloid Leukemia
Current Drug Targets Berberine Administration in Treatment of Colitis: A Review
Current Drug Targets TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies
Current Pharmaceutical Design GVHD: Complication and Challenge to Successful Allogeneic Hematopoietic Cell Transplantation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Recent Patents in the Field of Radioprotector Development: Opportunities and Challenges
Recent Patents on Biotechnology Anti-VEGF Anticancer Drugs: Mind the Hypertension
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes
Current Genomics The Cytoskeleton as a Therapeutic Target in Childhood Acute Leukemia:Obstacles and Opportunities
Current Drug Targets ASPM Predicts Poor Clinical Outcome and Promotes Tumorigenesis for Diffuse Large B-cell Lymphoma
Current Cancer Drug Targets Resveratrol: A New Potential Therapeutic Agent for Melanoma?
Current Medicinal Chemistry Sam Domains in Multiple Diseases
Current Medicinal Chemistry Current Advances in the Development of Anticancer Drugs Targeting Tyrosine Kinases of the Src Family
Current Drug Therapy Bladder Cancer and Stem Cells
Current Signal Transduction Therapy AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1
Current Cancer Drug Targets An Overview on Keratinocyte Growth Factor: From the Molecular Properties to Clinical Applications
Protein & Peptide Letters